Correction {#Sec1}
==========

The original article \[[@CR1]\] contains errors whereby some information provided in Tables [2](#Tab2){ref-type="table"} and [5](#Tab3){ref-type="table"} in the online version is missing in the PDF version; in addition, some details regarding the study by Mols et al., Johnstone et al. and Fransson et al. (2008) in Tables [1](#Tab1){ref-type="table"} and [5](#Tab3){ref-type="table"} require correction.Table 1Characteristics of included studiesAt survey ≥ 5 yearsMean/ Median (Range)^a^At diagnosis^g^First Author/ Year, CountryStudy DesignSample\
Size (n)Intervention (%)Age at survey (years)Follow-up time^f^\
(years)Cancer Stage (%)Berg, A/ 2007, Norway \[35\]Hospital-based observational prospective monocentric cohort study64EBRT (100) \[+ADT (44.0)\]^e^66^c^ (48-81)11 (10 -- 16)Localized PC (33.0)\
Locally advanced PC (67.0)Brundage, M/ 2015, UK and US \[36\]Hospital-based mulitcentric randomized controlled trial85-111^d^1. ADT (50.0)^c^\
2. ADT + EBRT (50.0)^c^69.7^c^ (65.5 -- 73.5)(5 -- 8)Locally advanced PC (100.0)Donovan, J L / 2016, UK \[37\]Population-based multicentric randomized controlled trial1413-1463^d^1. AS (33.2)\
2. RP (33.7)\
3. EBRT (33.1)62^c^(5 -- 6)Localized PC (100.0)Fransson, P/ 2008, Sweden \[38\]Hospital-based observational prospective monocentric cohort study641. EBRT (42.2) +ADT (20.3)\
2. Controls (57.8)78.1 (62 -- 87)14.7 (13.5 -- 16.4)Localized PC (89.9)\
Locally advanced PC (11.1)Fransson, P/ 2009, Sweden \[39\]Hospital-based observational monocentric retrospective cohort study541. EBRT (50.0)\
2. WW (50.0)78 (54 -- 88)9.6 (6.4 -- 16.3)Local PC (100.0)Galbraith, M E/ 2005, US \[40\]Hospital-based observational prospective monocentric cohort study1371. WW (11.5)^c^\
2. RP (21.4)^c^\
3. EBRT -- C (9.9)^b,c^\
4. EBRT - PB (11.5)^b,c^\
5. EBRT - MB (20.3) ^b,c^\
6. EBRT -LD (13.7)^b,c^\
7. EBRT - HD (17)^b,c^69.9^c^5.5No informationGiberti, C/ 2009, Italy \[41\]Hospital-based monocentric randomized controlled trial1741. RP (44.5)\
2. BT (55.5)65.3^c^ (56 -- 74)^c^5Localized PC (100.0)Johnstone, P A S/ 2000, US \[42\]Hospital based observational monocentric prospective cohort study46EBRT (100.0)\
\[+ ADT (43.5)\]^4^80 (62 -- 90)13.9 (10 -- 23)Localized PC\
Locally advanced PCMols, F/ 2006, Denmark \[43\]Population-based observational retrospective cohort study7801. RP (32.9)\
2. EBRT (41.4)\
3. ADT (13.7)\
4. WW (11.9)75(5-10)Localized PC (76.0)\
Locally Advanced PC (18.0)\
Unknown (6.0)Namiki, S/ 2011, Japan \[44\]Hospital-based observational prospective monocentric cohort study1111. RP (43.2) + ADT (48)\
2. EBRT (56.8) + ADT (100.0)69.5^c^ (53 -- 84)5Locally Advanced PC (100.0)Namiki, S/ 2014, Japan \[45\]Hospital-based observational prospective monocentric cohort study91RP (100.0)63.9^c^8.5 (7.1 -- 10.25)Localized PC (94.5)\
Locally Advanced PC (5.5)Shinohara, N/ 2013, Japan \[46\]Hospital-based observational monocentric prospective cohort study671. EBRT (32.4)\
2. RP (67.6)68^2^ (53 -- 79)5Localized PC (93.4)\
Locally Advanced PC (6.6)Thong, M S/ 2010, Netherlands \[47\]Population-based observational retrospective cohort study1421. AS (50.0) \[+ ADT (2.8)/ +RP (1.4)/ + EBRT (7)/ + EBRT + ADT (1.4)\]^e^\
2. EBRT (50) + \[RP (7)/ + ADT (2.8)/ +EBRT (1.4) + EBRT + ADT (1.4)\]^e^75.87.8Localized PC (100)*RP* Radical Prostatectomy, *EBRT* External Beam Radiotherapy (refers to the external delivery of any type of radiation), *BT* Brachytherapy, *WW* Watchful Waiting, *AS* Active Surveillance, *ADT* Androgen Deprivation Therapy^a^Mean/Medians for total sample^b^EBRT-C --- Conventional radiation; EBRT-HD --- High-dose mixed-beam radiation; EBRT-LD --- Low-dose mixed-beam radiation; EBRT-MB --- Standard protocol/mixed-beam radiation; EBRT-PB --- Proton beam radiation^c^Sample size/Age at enrolment in study or randomisation^d^Sample sizes at different time points ≥ 5 years^e^Secondary intervention(s)^f^Either time since diagnosis or time since randomization^g^Categorization: local PC -- T1 & T2, locally advanced PC T3 & T4Table 2Summary table of study characteristicsCharacteristicFrequencyStudy DesignRandomized controlled trial\
Observational prospective cohort study\
Observational retrospective cohort study3\
7\
3RecruitmentMonocentric hospital-based\
Multicentral hospital-based\
Population-based9\
1\
3Comparison: Intervention vs. general population\*RPEBRTADTWWASX2X^1a^5X1X1X1Comparison between different interventions\*RPEBRTADTWWASXXX1XX^d^1XX1X vs. X^c^1X^c^X1XX1XX1XXXX1XX^e^X1XX^f^1Sample sizes (total population)\<100\
101 -- 200\
780\
1463 (after 5 years since randomization) respectively 1413 participants (6 years since randomization)6\
5\
1\
1Years since diagnosis/randomizationLong-term survivors (5-10 years after diagnosis)\
Very long-term survivors (10 + years after diagnosis)10\
3Stage at diagnosisLocalized (T1/T2) PC\
Locally advanced (T3/T4 any N1/M1) PC\
Localized & locally advanced PC\
No information3\
2\
7\
1Recurrent PC survivorsNo information\
Excluded\
Included10\
1^g^\
2Progressive PC survivorsNo information\
Excluded\
Included5\
3\
5^a^Some studies had multiple comparisons^b^"Plus ADT and/or clinical progression"^c^plus ADT^d^Brachytherapy^e^EBRT-C --- Conventional radiation; EBRT-HD --- High-dose mixed-beam radiation; EBRT-LD --- Low-dose mixed-beam radiation; EBRT-MB --- Standard protocol/mixed-beam radiation; EBRT-PB --- Proton beam radiation^f^Brachytherapy^g^Excluded because they diedTable 5Main findings on HRQoL in observational studiesComp.StudyKey FindingsPotential Limitation(s)S1^a^Thong, M S/ 2010 \[47\]Comparison: AS vs. EBRT, follow-up time^b^: 7.8 years, mean age^d^: 75.8 years\
- No significant differences in HRQoL between AS and EBRT on the QOL-CS scales\
- In multivariate models EBRT was significantly negatively associated with physical functioning, bodily pain dimensions, QOL-CS spiritual and total well-being scores\
Subgroup analyses: exclusion of clinically progressed cancer survivors\
- Above results remain unchanged\
Comparison: AS or EBRT vs. controls from the general population, follow-up time^b^: 7.8 years, mean age^d^: 75.8 years\
- PC survivors reported comparable HRQoL scores compared to age-matched, normative population, except in role physical PC survivors treated with EBRT reported significantly (p\<0.05) worse mean compared to controls from the general population- No baseline data availableS2Namiki, S/ 2011 \[44\]Comparison: RP vs. EBRT, follow-up time^b^: 5 years, mean^e^: 69.5 years\
- Patterns of alterations over time in intervention groups were different in physical function (p\<0.001), role physical (p\<0.001), role emotional (p\<0.001) and vitality (p=0.027), whereas survivors treated with RP had higher scores in all domains- Sample size \<70 in all study arms\
- (Repeated ANOVA-tests: only changes over time are shown)\
- No confounding control\
- No adjustment for attrition errorS3^a^Berg, A/ 2007 \[35\]Comparison: EBRT + ADT/clinical progression vs. controls from the general population, follow-up time^b^: 10-16 years, median age^e^: 66 years\
- Worse clinically relevant scores for survivors in social functioning scales and higher burden with insomnia and diarrhea\
Comparison: EBRT vs. controls from the general population, follow-up time^c^: 10-16 years, median age^e^: 66 years\
- Clinically relevant higher burden for PC survivors with diarrhea- Sample size \<100 in all study arms\
- No confounding control\
- No significance statistical test\
-No adjustment for attrition errorS3^a^Fransson, P/ 2008 \[38\]Comparison: EBRT vs. controls from the general population, follow-up time^c^: 15 years, mean age^d^: 78.1 years\
- Significantly different (p\<0.05) worse mean for PC survivor in role function (clinically important difference)^f^ and higher burden with appetite loss, diarrhea (clinically important difference)^f^, nausea/vomiting and pain\
Comparison: EBRT vs. EBRT + ADT, follow-up time^c^: 15 years, mean age^d^: 78.1 years\
- No significant differences were observed among intervention groups in measures of general health-related or cancer-related QoL- Sample size \<100 in study arms\
- No confounding control\
- No adjustment for attrition errorS3Fransson, P/ 2009 \[39\]Comparison: EBRT vs. WW, follow-up time^c^: 10 years, median age^d^: 78 years\
- No significant differences were observed between groups in measures of general health-related or cancer-related QoL- Sample size \<100 in both study armsS3Johnstone, P A S/ 2000 \[42\]Comparison: EBRT (plus ADT) vs. controls from the general population, follow-up time^c^: 13.9 years, median age^d^: 80 years\
- Clinically important differences^f^ but worse scores for PC survivors in role emotional and vitality not statistically relevant- Sample size \<70 in study arm\
- No statistical significance test performed\
- No confounding control\
- No baseline dataS3Mols, F/ 2006 \[43\]Comparison: RP vs. EBRT (plus ADT) vs. ADT vs. WW, follow-up time^b^: 5-10 years, age^d^: average 80 years\
- PC survivors who underwent RP had, in general, the highest HRQoL, followed by survivors who received WW and patients who received EBRT. Survivors who received ADT had the lowest physical HRQL, in general.\
- Significantly different means between intervention groups in physical functioning (p \< 0.001, clinical important difference^f^) and physical well-being (p = 0.02). Clinically important differences^f^ in vitality among group means, but not significantly different means.\
- PC survivors treated with EBRT reported a significantly (p \< 0.05) worse mean in physical functioning compared to survivors treated with RP\
- Survivors treated with ADT reported a significantly (p\<0.05) worse mean in physical functioning and vitality compared to survivors treated with RP\
Subgroup analyses -- age groups: \<75 years vs. ≥75 years\
- In general, HRQoL scores were higher for younger survivors than for older survivors\
Comparison: RP or EBRT or ADT or WW vs. general population, 5-10 years after diagnosis\
- PC survivors reported comparable HRQoL scores compared to an age-matched, normative population group\
- PC survivors treated with RP, EBRT and WW reported less problems with bodily pain than population controls- Sample size \<70 in two (ADT & WW) out of 4 study arms in general analyses\
- Sample size \<70 in three out of 4 study arms (RP, ADT & WW) in subgroup analyses\
- No baseline data availableS3Namiki, S/ 2014 \[45\]Comparison: RP vs. controls from the general population, follow-up time^c^: 8.3 years, mean age^d^: 63.9 years\
- No significant differences were observed among the groups in measures of general health-related or cancer-related quality of life- Sample size \<70 in study arms\
- No adjustment for attrition errorS3^a^Shinohara, N/ 2013 \[46\]Comparison: EBRT vs. RP, localized and locally advanced PC, follow-up time: 5 years, mean/median age: 68 years\
- No significant differences were observed among the groups in measures of general health-related or cancer-related QoL- Sample size \<70 in all study arms\
- No adjustment for attrition error\
- No confounding controlXGalbraith, M E/ 2005 \[30\]Comparison: EBRT -- LD^g^, EBRT -- C^g^ vs. WW, follow-up time^c^: 5.5 years, age^d^: average 69.7 years\
- Regardless of type of intervention, health-related QOL and general health tend to decrease for prostate cancer survivors\
- PC survivors in WW tended to have poorer health outcomes- Sample size \<70 in all study arms\
- No confounding control\
- For growth curve analyses plots are printed badly, so it cannot be distinguished between intervention arms\
- For comparisons at specific time points it is not explained which statistical tests was used\
- P-values are not shown for all comparisons, not explained for which reasons some results are not shown\
- No adjustment for attrition errorComp. Comparison groupS1: HRQoL by primary intervention in long-term survivors with localized PC; S2: HRQoL by intervention in long-term survivors with locally advanced PC; S3: HRQoL by intervention in long-term survivors with localized or locally advanced PC; X: No assignment possible as study revealed no information about cancer stageStudies were ordered by stage information and within each group alphabetically.As potential limitations, the following criteria were considered: (1) sample size 100 per study arm for studies using EORTC-C30 and 70 for studies using SF-36 70 (2) adjustment for attrition error (3) statistical significance tests performed (4) adjustment for attrition error (only prospective cohort studies) (5) baseline data available (6) reporting of appropriate results.Definition of clinically meaningful difference: EORTC QLQ-C30: min. 10 points difference; SF-36: min. 5 points difference in general health dimension, min 6.5 points in physical dimension, 7.9 points in mental health dimension.^a^Inlcusion of PC survivors with disease progression^b^Time since diagnosis^c^Time since enrolment in study^d^Age at survey^e^Age at enrollment in study^f^Not reported, but clinically meaningful difference^g^EBRT-LD --- Low-dose mixed-beam radiation, EBRT-C --- Conventional radiation

As such, the corrected tables can be seen ahead.
